AACR-NCI-EORTC 2025 Poster A045

Development of Patient-Derived Xenograft (PDX) with Acquired Resistance to KRASG12C Inhibitors

Aaron Li Hua, Jinxi Wang, Qingzhi Liu, Tina Zhang, Wubin Qian, Ludovic Bourre, Jessie JingJing Wang

KRAS G12C mutations drive a significant subset of non–small cell lung cancer (NSCLC), but resistance to targeted therapies remains a major barrier. Crown Bioscience developed patient-derived xenograft (PDX) models with acquired resistance to KRAS G12C inhibitors to better understand and overcome these mechanisms.

These novel PDX models replicate the evolution of drug resistance observed clinically and provide a platform for combination testing and biomarker discovery.

Download this Poster to Discover:

• How resistant PDX models were established from KRAS^G12C inhibitor–treated tumors
• Key findings on EGFR and MET gene amplifications driving resistance
• The effect of combining AMG510 and crizotinib in overcoming resistance
• How these models can accelerate preclinical testing of next-generation inhibitors

Download the Poster Now!